We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+35.87%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$211M
AUM Growth
-$31.9M
Cap. Flow
-$83.2M
Cap. Flow %
-39.42%
Top 10 Hldgs %
8.5%
Holding
499
New
89
Increased
112
Reduced
218
Closed
57

Sector Composition

Rank Sector Weight
1 Healthcare 33.94%
2 Real Estate 15.9%
3 Energy 15.5%
4 Materials 8.79%
5 Financials 7.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MTEM
276
DELISTED
Molecular Templates, Inc.
MTEM
$341K 0.16%
+1,650
New +$383K
CUE icon
277
Cue Biopharma
CUE
$127M
$336K 0.16%
+457
New +$331K
SNDX icon
278
Syndax Pharmaceuticals
SNDX
$1.74B
$335K 0.16%
+22,596
New +$344K
RETA
279
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$335K 0.16%
2,146
+408
+23% +$62K
PRVL
280
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$335K 0.16%
+22,460
New +$346K
BLUE
281
DELISTED
bluebird bio
BLUE
$334K 0.16%
423
+114
+37% +$86K
RLMD icon
282
Relmada Therapeutics
RLMD
$549M
$334K 0.16%
+7,463
New +$316K
NGM
283
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$334K 0.16%
+16,913
New +$323K
BLW icon
284
BlackRock Limited Duration Income Trust
BLW
$491M
$333K 0.16%
23,884
-104,739
-81% -$1.41M
MGTX icon
285
MeiraGTx Holdings
MGTX
$1.09B
$332K 0.16%
26,545
+9,431
+55% +$131K
EVF
286
Eaton Vance Senior Income Trust
EVF
$89.9M
$331K 0.16%
62,073
-259,716
-81% -$1.33M
HARP
287
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$330K 0.16%
+1,986
New +$310K
IOVA icon
288
Iovance Biotherapeutics
IOVA
$2.1B
$326K 0.15%
11,869
-1,882
-14% -$61.9K
KOD icon
289
Kodiak Sciences
KOD
$2.52B
$326K 0.15%
6,026
+359
+6% +$20.2K
FCT
290
First Trust Senior Floating Rate Income Fund II
FCT
$251M
$324K 0.15%
29,761
-148,464
-83% -$1.57M
VIE
291
DELISTED
Viela Bio, Inc. Common Stock
VIE
$324K 0.15%
+7,486
New +$339K
KRYS icon
292
Krystal Biotech
KRYS
$10.7B
$322K 0.15%
7,784
+2,268
+41% +$109K
BGT icon
293
BlackRock Floating Rate Income Trust
BGT
$322M
$319K 0.15%
29,078
-129,190
-82% -$1.37M
NXTC icon
294
NextCure
NXTC
$22.1M
$316K 0.15%
1,229
+651
+113% +$248K
RCUS icon
295
Arcus Biosciences
RCUS
$3.4B
$312K 0.15%
+12,599
New +$340K
APLT
296
DELISTED
Applied Therapeutics
APLT
$311K 0.15%
+8,605
New +$360K
CCXI
297
DELISTED
ChemoCentryx, Inc.
CCXI
$310K 0.15%
5,386
-6,061
-53% -$330K
BRW
298
Saba Capital Income & Opportunities Fund
BRW
$336M
$309K 0.15%
37,940
-160,402
-81% -$1.28M
WHF icon
299
WhiteHorse Finance
WHF
$139M
$308K 0.15%
29,922
-227,812
-88% -$2.12M
RVMD icon
300
Revolution Medicines
RVMD
$39.1B
$306K 0.14%
+9,701
New +$305K

Similar funds

Virtus ETF Advisers's Q2 2020 Portfolio in Review

As of Q2 2020, Virtus ETF Advisers held 499 positions worth $211M, down 13% from $243M the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.

Virtus ETF Advisers withdrew a net $83.2M in Q2 2020, closing 57 positions and reducing 218 holdings. Its most notable exit was Tallgrass Energy, LP Class A Shares, an estimated $1.22M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, up from 20% a quarter earlier, followed by Real Estate and Energy.

Against the trend, Virtus ETF Advisers opened a new position in Verastem worth $342K.

  • Virtus ETF Advisers's largest Q2 2020 buy was Verastem: 16,584 shares worth $342K.
  • Virtus ETF Advisers added most to Delek Logistics in Q2 2020, an estimated $1.29M increase.
  • Virtus ETF Advisers's biggest Q2 2020 reduction was Barings BDC, cutting an estimated $2.49M.
  • Virtus ETF Advisers fully exited Tallgrass Energy, LP Class A Shares in Q2 2020, selling an estimated $1.22M.
  • Virtus ETF Advisers's ten largest holdings make up 8.5% of its $211M portfolio in Q2 2020.
  • Virtus ETF Advisers opened 89 new positions and closed 57 in Q2 2020.
  • Virtus ETF Advisers's portfolio value fell 13% quarter-over-quarter to $211M.

Based on Virtus ETF Advisers's 13F filing for Q2 2020, filed 5 Aug 2020.